[Evaluation of expression and correlation between P53, BCL-2 and BAX proteins in ovarian neoplasms].
OBJECTIVE
Interactions between BCL-2 and other proteins regulating programmed cells death in ovarian carcinomas are poorly understood.


METHODS
The evaluation of expression of P53, BCL-2 and BAX proteins in ovarian carcinomas. The associations between oncoproteins studied and the histological structure, grade of differentiation and stage of disease were also analysed.


METHODS
The expression of P53, BCL-2 and BAX was evaluated by immunoperoxidase technique (PAP) in tissue sections and corresponding cyst and/or ascitic fluid cells in individual patients with ovarian carcinoma.


RESULTS
It was shown that the expression of P53 and BAX was comparable in tissue sections and cyst or ascitic fluid cells of individual patients, however the presence of BCL-2 was detected more frequently in tissue sections. No correlations between markers studied and histological subtypes and grade of carcinoma were found. Taking into account the relationship between P53, BCL-2 and BAX expression, it was possible to classify the studied ovarian carcinomas into four phenotypes. Ovarian cancers with phenotype P53+/BCL-2- were more frequent in III/IV degree FIGO stages whereas the phenotype P53-/BCL-2+ were identified mainly in patients in I/II degree FIGO stages. The progression of disease and death occurred more frequently in groups with phenotype P53+/BCL-2+ and P53-/BCL-2-.


CONCLUSIONS
Our observations indicated that estimation of P53, BCL-2 and BAX protein expression may be important in the choice of the chemotherapy.
Bar
Julia Krystyna
JK
Katedry i Zakładu Immunologii Klinicznej Akademii Medycznej we Wrocławiu.
Sobańska
Ewa
E
Popiela
Andrzej
A
Goluda
Marian
M
D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins; D000072224:Bcl-2-Like Protein 11; D014408:Biomarkers, Tumor / Q000032:analysis*; D002352:Carrier Proteins / Q000032:analysis*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008565:Membrane Proteins; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000473:pathology; D010641:Phenotype; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D051028:bcl-2-Associated X Protein
D051017:Apoptosis Regulatory Proteins; C494826:BAX protein, human; C000606775:BCL2L11 protein, human; D000072224:Bcl-2-Like Protein 11; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein